DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Casimersen
Casimersen
Refreshing the Biologic Pipeline 2020
213026Orig1s000
Rxoutlook® 1St Quarter 2019
Effectiveness of Pharmacological Treatments in Duchenne Muscular Dystrophy: a Protocol for a Systematic Review and Meta-Analysis
Medical Record Requirements for Pre-Service Reviews
Virtual Posters
213026Orig1s000
Aetna PA Info
Stanford Neuromuscular Research Program Newsletter: Issue 6 a Message from Dr
RNA Therapeutics on the Rise
Research Overview: the Landscape and the Opportunities Duchenne Muscular Dystrophy
5.01.570 Pharmacologic Treatment of Duchenne Muscular Dystrophy
Medical Benefit Injectable Drugs | Kaiser Permanente Washington
Blue Cross and BCN Utilization Management Medical Drug List
Amondys 45™ (Casimersen)
Serve You Rx Prior Authorization Information and Drug List
Authorization Requirements Medicare
Results from the Muscular Dystrophy Association DMD Clinical Research Network
Top View
Medications for Duchenne Muscular Dystrophy SERVICE: Casimersen
High Potential Disruption Report May 2020
Nonpayable Drug List
Injections: Drugs AD Policy
Application Number
Current Status of Antisense Oligonucleotide-Based Therapy in Neuromuscular Disorders Flavien Bizot, Adeline Vulin, Aurélie Goyenvalle
Drug Coverage Guidelines – Oxford Clinical Policy
Effectiveness of Pharmacological Treatments In
Connecticare Commercial Connecticare Commercial J7192 Advate (Factor VIII)
Prior Authorization List* for Blue Shield and FEP Members Effective July 1, 2021
Deflazacort, Eteplirsen, and Golodirsen for Duchenne Muscular Dystrophy: Effectiveness and Value
Brand Pipeline Forecast 4Th Quarter 2019
A View Into Upcoming Specialty & Traditional Drugs
213026Orig1s000
Therapeutic Strategies for Duchenne Muscular Dystrophy: an Update
Therapeutic Class Overview Duchenne Muscular Dystrophy (DMD) Agents
Prior Authorization and Investigational Services List
CCS NL 02-0321 Treatment Of
Duchenne Research Overview: New and Emerging Therapies
Orange Book Cumulative Supplement 7 July 2021
Amondys 45™ (Casimersen) (For Louisiana Only) Policy Number: CSLA2021D00105A Effective Date: Instructions for Use
2020 Medicines in Development for Children
Drugs That Require Prior Authorization
Amondys 45) Reference Number: ERX.SPA.382 Effective Date: 02.25.21 Last Review Date: 05.21 Line of Business: Commercial, Medicaid Revision Log
Amondys 45™ (Casimersen) – Commercial Medical Benefit Drug
Outpatient Drug Services Handbook
Providers | Gene Based Therapy for Duchenne Muscular Dystrophy Policy
The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery